Axial Spondylarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major axial spondylarthritis markets reached a value of US$ 6.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.
The axial spondylarthritis market has been comprehensively analyzed in IMARC's new report titled "Axial Spondylarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Axial spondyloarthritis refers to a chronic inflammatory disease that primarily affects the axial skeleton, which includes the spine and the sacroiliac joints connecting the spine to the pelvis. The primary symptom associated with the ailment is back pain, characterized by stiffness and pain in the lower back that is worse in the morning or after periods of inactivity and improves with movement. Various other indications may include peripheral joint involvement, enthesitis (inflammation at tendon and ligament insertions), dactylitis (swelling of an entire finger or toe), uveitis (eye inflammation), extra-articular manifestations like psoriasis or inflammatory bowel disease, etc. Diagnosing axial spondyloarthritis involves a comprehensive evaluation that combines clinical assessment, imaging techniques, laboratory tests, as well as symptom examination. Numerous imaging modalities, such as X-rays and magnetic resonance imaging (MRI), play a crucial role in detecting structural changes and inflammation in the spine and sacroiliac joints. Several other laboratory procedures may include measuring inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), as well as genetic testing for the HLA-B27 marker.
The increasing incidences of immune system dysregulation, in which the immune system may overreact and trigger an abnormal inflammatory response, thereby leading to chronic inflammation in the axial skeleton, are primarily driving the axial spondylarthritis market. In addition to this, the rising cases of alterations in the composition and diversity of gut bacteria that may disrupt immune homeostasis and contribute to the development of inflammatory conditions are further creating a positive outlook for the market. Moreover, the widespread adoption of disease-modifying antirheumatic drugs (DMARDs), including sulfasalazine or methotrexate, which modify the immune response and reduce inflammation, is also bolstering the market growth. Additionally, the inflating application of various pain management techniques, such as heat or cold therapy, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc., since they can help in alleviating pain and stiffness associated with the ailment, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of several radiographic scoring systems like the Stoke Ankylosing Spondylitis Spinal Score that assist in evaluating the presence of structural damage, including syndesmophytes and joint erosions, thereby aiding in diagnosis and monitoring disease progression, is expected to drive the axial spondylarthritis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the axial spondylarthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for axial spondylarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the axial spondylarthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the axial spondylarthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the axial spondylarthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current axial spondylarthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the axial spondylarthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the axial spondylarthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the axial spondylarthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with axial spondylarthritis across the seven major markets?
What is the size of the axial spondylarthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of axial spondylarthritis?
What will be the growth rate of patients across the seven major markets?
Axial Spondylarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for axial spondylarthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the axial spondylarthritis market?
What are the key regulatory events related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by status related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by phase related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by route of administration related to the axial spondylarthritis market?
The axial spondylarthritis market has been comprehensively analyzed in IMARC's new report titled "Axial Spondylarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Axial spondyloarthritis refers to a chronic inflammatory disease that primarily affects the axial skeleton, which includes the spine and the sacroiliac joints connecting the spine to the pelvis. The primary symptom associated with the ailment is back pain, characterized by stiffness and pain in the lower back that is worse in the morning or after periods of inactivity and improves with movement. Various other indications may include peripheral joint involvement, enthesitis (inflammation at tendon and ligament insertions), dactylitis (swelling of an entire finger or toe), uveitis (eye inflammation), extra-articular manifestations like psoriasis or inflammatory bowel disease, etc. Diagnosing axial spondyloarthritis involves a comprehensive evaluation that combines clinical assessment, imaging techniques, laboratory tests, as well as symptom examination. Numerous imaging modalities, such as X-rays and magnetic resonance imaging (MRI), play a crucial role in detecting structural changes and inflammation in the spine and sacroiliac joints. Several other laboratory procedures may include measuring inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), as well as genetic testing for the HLA-B27 marker.
The increasing incidences of immune system dysregulation, in which the immune system may overreact and trigger an abnormal inflammatory response, thereby leading to chronic inflammation in the axial skeleton, are primarily driving the axial spondylarthritis market. In addition to this, the rising cases of alterations in the composition and diversity of gut bacteria that may disrupt immune homeostasis and contribute to the development of inflammatory conditions are further creating a positive outlook for the market. Moreover, the widespread adoption of disease-modifying antirheumatic drugs (DMARDs), including sulfasalazine or methotrexate, which modify the immune response and reduce inflammation, is also bolstering the market growth. Additionally, the inflating application of various pain management techniques, such as heat or cold therapy, transcutaneous electrical nerve stimulation (TENS), acupuncture, etc., since they can help in alleviating pain and stiffness associated with the ailment, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of several radiographic scoring systems like the Stoke Ankylosing Spondylitis Spinal Score that assist in evaluating the presence of structural damage, including syndesmophytes and joint erosions, thereby aiding in diagnosis and monitoring disease progression, is expected to drive the axial spondylarthritis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the axial spondylarthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for axial spondylarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the axial spondylarthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the axial spondylarthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the axial spondylarthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current axial spondylarthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the axial spondylarthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the axial spondylarthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the axial spondylarthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axial spondylarthritis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with axial spondylarthritis across the seven major markets?
What is the size of the axial spondylarthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of axial spondylarthritis?
What will be the growth rate of patients across the seven major markets?
Axial Spondylarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for axial spondylarthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the axial spondylarthritis market?
What are the key regulatory events related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by status related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by phase related to the axial spondylarthritis market?
What is the structure of clinical trial landscape by route of administration related to the axial spondylarthritis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AXIAL SPONDYLARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AXIAL SPONDYLARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AXIAL SPONDYLARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AXIAL SPONDYLARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AXIAL SPONDYLARTHRITIS - UNMET NEEDS
10 AXIAL SPONDYLARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 AXIAL SPONDYLARTHRITIS - MARKETED PRODUCTS
11.1 List of Axial Spondylarthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Humira (Adalimumab) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Enbrel (Etanercept) - Amgen/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Simponi (Golimumab)- Janssen Pharmaceutical Companies
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Taltz (Ixekizumab)- Eli Lilly and Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rinvoq (Upadacitinib)- AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AXIAL SPONDYLARTHRITIS - PIPELINE DRUGS
12.1 List of Axial Spondylarthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Filgotinib - Galapagos NV
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AXIAL SPONDYLARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AXIAL SPONDYLARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AXIAL SPONDYLARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Axial Spondylarthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Axial Spondylarthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Axial Spondylarthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Axial Spondylarthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Axial Spondylarthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Axial Spondylarthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Axial Spondylarthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Axial Spondylarthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Axial Spondylarthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Axial Spondylarthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Axial Spondylarthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Axial Spondylarthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Axial Spondylarthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Axial Spondylarthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Axial Spondylarthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Axial Spondylarthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Axial Spondylarthritis - Access and Reimbursement Overview
16 AXIAL SPONDYLARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AXIAL SPONDYLARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AXIAL SPONDYLARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AXIAL SPONDYLARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AXIAL SPONDYLARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AXIAL SPONDYLARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AXIAL SPONDYLARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AXIAL SPONDYLARTHRITIS - UNMET NEEDS
10 AXIAL SPONDYLARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 AXIAL SPONDYLARTHRITIS - MARKETED PRODUCTS
11.1 List of Axial Spondylarthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Humira (Adalimumab) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Enbrel (Etanercept) - Amgen/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Simponi (Golimumab)- Janssen Pharmaceutical Companies
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Taltz (Ixekizumab)- Eli Lilly and Company
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rinvoq (Upadacitinib)- AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AXIAL SPONDYLARTHRITIS - PIPELINE DRUGS
12.1 List of Axial Spondylarthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 Filgotinib - Galapagos NV
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AXIAL SPONDYLARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AXIAL SPONDYLARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AXIAL SPONDYLARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Axial Spondylarthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Axial Spondylarthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Axial Spondylarthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Axial Spondylarthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Axial Spondylarthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Axial Spondylarthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Axial Spondylarthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Axial Spondylarthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Axial Spondylarthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Axial Spondylarthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Axial Spondylarthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Axial Spondylarthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Axial Spondylarthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Axial Spondylarthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Axial Spondylarthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Axial Spondylarthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Axial Spondylarthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Axial Spondylarthritis - Access and Reimbursement Overview
16 AXIAL SPONDYLARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AXIAL SPONDYLARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AXIAL SPONDYLARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
